Interim Analysis Shows Abiraterone Acetate Significantly Improves Radiographic Progression-Free Survival in Chemo-Naïve Metastatic Castration-Resistant Prostate Cancer

Share this content:
Interim Analysis Shows Abiraterone Acetate Significantly Improves Radiographic Progression-Free Surv
Interim Analysis Shows Abiraterone Acetate Significantly Improves Radiographic Progression-Free Surv

CME

Program Description:

Patients with asymptomatic and mildly symptomatic chemotherapy-naïve metastatic castration-resistant prostate cancer had significantly improved radiographic progression-free survival (rPFS) and showed a strong trend for increased overall survival (OS) following treatment with abiraterone acetate plus prednisone compared with prednisone alone, according to second interim analysis results of a study presented at the 2012 Annual Meeting of the American Society of Clinical Oncology.

INTENDED AUDIENCE:

Physicians, nurse practitioners, physician assistants, nurses, and other healthcare providers who manage patients with prostate cancer.

Activity Objectives:

After participating in this educational activity, participants should be better able to:

  • Analyze the impact of abiraterone acetate plus prednisone on pain palliation, delayed pain progression, and delayed time to skeletal-related events.

  • Integrate new approaches into the management of adults with metastatic castration-resistant prostate cancer.

Click Next to begin the activity.

Page 1 of 4

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs